These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30215805)

  • 21. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.
    Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
    J Crohns Colitis; 2014 Sep; 8(9):1022-9. PubMed ID: 24566170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma.
    Nagata N; Sakamoto K; Arai T; Niikura R; Shimbo T; Shinozaki M; Aoki T; Kishida Y; Sekine K; Tanaka S; Okubo H; Watanabe K; Sakurai T; Yokoi C; Akiyama J; Yanase M; Noda M; Itoh T; Mizokami M; Uemura N
    Int J Cancer; 2014 Nov; 135(10):2273-81. PubMed ID: 24692064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parameters of body composition and creeping fat are associated with activity of Crohn's disease.
    Barajas Ordonez F; Melekh B; Rodríguez-Feria P; Damm R; Thormann M; March C; Omari J; Pech M; Surov A
    Magn Reson Imaging; 2023 May; 98():1-6. PubMed ID: 36634829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors.
    Abraham TM; Pedley A; Massaro JM; Hoffmann U; Fox CS
    Circulation; 2015 Oct; 132(17):1639-47. PubMed ID: 26294660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
    Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
    Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.
    Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P
    Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease?
    Zulian A; Cancello R; Micheletto G; Gentilini D; Gilardini L; Danelli P; Invitti C
    Gut; 2012 Jan; 61(1):86-94. PubMed ID: 21930728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up.
    Jones GR; Fascì-Spurio F; Kennedy NA; Plevris N; Jenkinson P; Lyons M; Wong L; MacLean P; Glancy S; Lees CW
    J Crohns Colitis; 2019 Mar; 13(4):442-450. PubMed ID: 30452618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abdominal Adiposity Distribution Quantified by Ultrasound Imaging and Incident Hypertension in a General Population.
    Seven E; Thuesen BH; Linneberg A; Jeppesen JL
    Hypertension; 2016 Nov; 68(5):1115-1122. PubMed ID: 27620395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia.
    Bryant RV; Schultz CG; Ooi S; Goess C; Costello SP; Vincent AD; Schoeman SN; Lim A; Bartholomeusz FD; Travis SPL; Andrews JM
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30200405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations of Abdominal Subcutaneous and Visceral Fat with Insulin Resistance and Secretion Differ Between Men and Women: The Netherlands Epidemiology of Obesity Study.
    de Mutsert R; Gast K; Widya R; de Koning E; Jazet I; Lamb H; le Cessie S; de Roos A; Smit J; Rosendaal F; den Heijer M
    Metab Syndr Relat Disord; 2018 Feb; 16(1):54-63. PubMed ID: 29338526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal calprotectin in the prediction of postoperative recurrence of Crohn's disease in children and adolescents.
    Hukkinen M; Pakarinen MP; Merras-Salmio L; Koivusalo A; Rintala R; Kolho KL
    J Pediatr Surg; 2016 Sep; 51(9):1467-72. PubMed ID: 26891835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
    Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
    World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines.
    Bourgonje AR; von Martels JZH; de Vos P; Faber KN; Dijkstra G
    PLoS One; 2018; 13(2):e0193202. PubMed ID: 29466406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.